Hormonal
Tirzepatide significantly reduces apnea-hypopnea index (AHI) and resolves obstructive sleep apnea (OSA) in obese patients, with approximately 50% achieving resolution after 52 weeks of treatment.
If you have obesity and OSA, tirzepatide (10-15mg weekly) can significantly reduce your apnea severity and may even resolve OSA in half of users after one year. It is not a quick fix; it takes time to lose weight. For severe cases, it should be used alongside CPAP initially, with the goal of potentially reducing CPAP dependence as weight loss occurs. Long-term use is likely necessary to maintain benefits.
There were robust decrements in AHI with resolution of OSA in approximately 50% of subjects.
Why this rating
Based on the SURMOUNT-OSA trial, a landmark double-blind randomized controlled trial with p < .001.
Source
What will the impact be of use of tirzepatide in patients with obstructive sleep apnea (OSA)?
Allan I Pack et al. · SLEEP · 2025
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →